<img alt="" src="https://secure.lote1otto.com/219869.png" style="display:none;">
Skip to content

Bayesian Dose Escalation Designs for Late Onset Toxicity

| |

Last week Cytel joined forces with Sanofi/Genzyme to devote a full day of workshops and talks related to modern methods in early phase oncology. 

Li Liu, the Assistant Director of Biostatistics at Sanofi, kicked off the day with this talk on Bayesian dose-escalation designs with considerations for late onset toxicity. Li shows that in order to account for both dose-limiting toxicity and late onset toxicity, trial designs may have to  move beyond the standard use of escalation with overdose control (EWOC). 

Click to watch how incorporating Bayesian strategies can help overcome this common problem.